Vonvendi in India
How patients in India access Vonvendi (recombinant vWF) via Named Patient Program.
Vonvendi - overview
Vonvendi (recombinant vWF) is manufactured by Takeda and indicated for on-demand treatment and routine prophylaxis of bleeding episodes, and perioperative management of bleeding, in adults and children with von Willebrand disease. It is an intravenous recombinant VWF concentrate approved by the US FDA in 2015 and may be accessible to patients in India through a Named Patient Program or personal-import pathway.
Access in India
India's CDSCO permits import of unapproved drugs under Rule 36 for personal use by patients with a prescription from a registered medical practitioner. Named Patient import is common for rare-disease indications.
How Reserve Meds coordinates access in India
- Patient or treating physician submits a request.
- We verify clinical appropriateness and India-specific eligibility.
- Treating physician in India issues prescription and clinical justification.
- Country-specific NPP/personal-import forms are prepared and filed.
- We source Vonvendi from a DSCSA-compliant US specialty wholesaler.
- Cold-chain shipment to the patient's physician or hospital pharmacy in India.
Typical timeline for India
End-to-end, most requests are completed in 2-6 weeks. India's tier 1 regulatory maturity typically supports fast processing times.
What patients and physicians in India ask
- Is the pathway legal in India? Yes - it operates under India's established NPP or personal-import framework.
- Does my insurance cover it? Typically no for NPP drugs; patient prepayment is standard.
- What physician credentials do I need? A licensed physician in India able to issue the prescription and clinical justification.
- What if the drug is in shortage? We will inform you upfront and decline rather than promise what we cannot deliver.
- Can I re-supply? Yes - for chronic therapies we arrange ongoing re-supply.